《大行報告》大和降石藥(01093.HK)評級至「跑贏大市」 目標價下調至6.5元
大和發表研究報告指,石藥(01093.HK)的第二季業績大致符合預期,收入按年增3.8%至80億元人民幣,毛利率71.2%,純利15億元人民幣。該行表示,由於預期在中國醫藥領域反腐敗工作期間,公司的銷售將會減慢,加上預計研發費用將會增加8至9%,故下調其2023至25年的收入預測2至3%,每股盈測則降3至7%。
該行表示,由於下調2023至25年的盈測及料自由現金流利潤率降低2至4個百分點,將集團評級由「買入」下調至「跑贏大市」,目標價由8.4元降至6.5元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.